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Intracellular cobalamin is converted to adenosylco-
balamin, coenzyme for methylmalonyl-CoA mutase and
to methylcobalamin, coenzyme for methionine synthase,
in an incompletely understood sequence of reactions.
Genetic defects of these steps are defined as cbl comple-
mentation groups of which cblC, cblD (described in only
two siblings), and cblF are associated with combined
homocystinuria and methylmalonic aciduria. Here we
describe three unrelated patients belonging to the cblD
complementation group but with distinct biochemical
phenotypes different from that described in the original
cblD siblings. Two patients presented with isolated ho-
mocystinuria and reduced formation of methionine and
methylcobalamin in cultured fibroblasts, defined as
cblD-variant 1, and one patient with isolated methylma-
lonic aciduria and deficient adenosylcobalamin synthe-
sis in fibroblasts, defined as cblD-variant 2. Cell lines
from the cblD-variant 1 patients clearly complemented
reference lines with the same biochemical phenotype,
i.e. cblE and cblG, and the cblD-variant 2 cell line com-
plemented cells from the mutant classes with isolated
deficiency of adenosylcobalamin synthesis, i.e. cblA and
cblB. Also, no pathogenic sequence changes in the cod-
ing regions of genes associated with the respective bio-
chemical phenotypes were found. These findings indi-
cate heterogeneity within the previously defined cblD
mutant class and point to further complexity of intra-
cellular cobalamin metabolism.
Cobalamin (cbl,1 vitamin B12) serves as the cofactor for two
enzymes in humans. Mitochondrial methylmalonyl-CoA mu-
tase (MMA-CoA mutase; EC 5.4.99.2) requires 5-deoxyadeno-
sylcobalamin (AdoCbl), and N5-methyltetrahydrofolate:homo-
cysteine methyltransferase (methionine synthase, EC 2.1.1.13)
is dependent on methylcobalamin (MeCbl).
To fulfill its cofactor function dietary cbl must be absorbed,
transported in the bloodstream, and taken up into cells in a
complex series of processes involving specific receptors and
carrier proteins (1). Intracellular processing is also complex
and not fully understood. After release of lysosomal cbl into the
cytosol, reduction of cob(III)alamin to cob(I)alamin is followed
by reductive methylation on the methionine synthase enzyme
in the cytosol, or by attachment of an adenosyl group in the
mitochondrion. A number of rare defects in these intracellular
processing steps are known, causing disease of varying sever-
ity. So far eight cbl complementation groups have been linked
to these disorders (see “Discussion” for further details).
The cblE (MIM 236270) and cblG (MIM 250940) complemen-
tation groups represent defects of methionine synthase reduc-
tase (EC 2.1.1.135; MTRR gene) and methionine synthase
(MTR gene), respectively, both causing isolated homocystin-
uria (2–4). Banerjee and coworkers have shown that another
system, comprising soluble cytochrome b5 and novel reductase
1 (NR1), is able to reductively activate methionine synthase, in
addition to methionine synthase reductase. However, the func-
tional significance of this system remains unclear (5).
The cblA (MIM 251100), cblB (MIM 251110), and cblH (MIM
606169) complementation groups are linked to processes
unique to AdoCbl synthesis and cause isolated methylmalonic
aciduria (MMA-uria) (6, 7). Genes for the cblA (MMAA) and
cblB (MMAB) groups have recently been described, although
the corresponding proteins have not yet been characterized.
The deduced amino acid sequence of the MMAA gene points to
a transporter or accessory protein involved in translocation of
cbl into the mitochondrion (8). The MMAB gene appears to code
for cbl adenosyltransferase (EC 2.5.1.7) (9). Only one patient
has been designated to the cblH complementation group, and
nothing is known about the corresponding gene or protein (7).
Isolated MMA-uria is also caused by defects of the MMA-CoA
mutase apoenzyme (EC 5.4.99.2), designated the mut comple-
mentation group. The majority of patients have complete en-
zyme deficiency (mut0), whereas some (mut) show residual
enzyme activity with reduced affinity for AdoCbl, and hydroxo-
cobalamin (OH-Cbl) responsiveness in fibroblasts (6).
The cblF (MIM 277380), cblC (MIM 277400), and cblD (MIM
277410) complementation groups affect early steps of intracel-
lular cbl processing and cause combined homocystinuria with
MMA-uria (1). The cblF defect is due to disturbed lysosomal
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release of OH-Cbl into cytoplasm (10). The defect in the cblC
and cblD groups is likely to involve cytosolic reduction of cbl as
suggested by two reports (11, 12), but the exact metabolic steps
and mechanisms remain unclear. Cbl--ligand transferase ac-
tivity was shown to be reduced to 2–34% of the mean control
value in four cblC cell lines but was also low (30%) in a cblD cell
line (11). Thus the role of this enzyme in the cblC disorder
remains to be confirmed. The cblD complementation group has
so far only been assigned to two siblings (13) described in 1970
(14), whereas more than a hundred patients belonging to the
cblC group have been reported (6). Studies of enzyme activities
and cbl metabolism in fibroblasts of the cblD siblings revealed
similar but less severe abnormalities compared with those
found in cblC cells (15, 16).
Clinical presentation varies greatly both between and within
the complementation groups. Patients with homocystinuria,
isolated or in combination with MMA-emia, present with meg-
aloblastic anemia and various neurological abnormalities (1,
17) and have, at least to some degree, responded biochemically
and clinically to vitamin B12 therapy. Patients with isolated
MMA-emia usually present with metabolic decompensation
and show lethargy, failure to thrive, feeding problems, and
muscular hypotonia but no signs of megaloblastic anemia (6).
We present evidence for heterogeneity within the cblD
complementation group based on biochemical findings and de-
tailed enzyme studies in cultured skin fibroblasts in three new
unrelated patients. In contrast to the previously reported cblD
siblings, one patient revealed isolated MMA-uria, the other two
isolated homocystinuria, although each belongs to the cblD
complementation group when investigated by somatic comple-
mentation in cultured fibroblasts.
CASE REPORTS
Patient 1, born after uneventful pregnancy, was of Irish
origin. Family relationships were complicated and suggested
high grade consanguinity. At 6 years of age he presented with
global developmental delay, severe learning difficulties and
spastic ataxia, absence of ankle jerks, and rapid deterioration
of gait. His weight and head circumference were at the 50th
percentile. He had no vocal skills, made no eye contact, and on
attempting to walk he held his arms abducted and flexed at the
elbow. Reflexes were present in the upper limbs but absent in
the lower limbs. A cranial MRI scan revealed cerebral and
cerebellar atrophy. Visually evoked responses were poorly
formed and delayed, and an electroretinogram analysis was
normal. The mean corpuscular volume was elevated (94 fl;
normal range, 70–87), but hemoglobin (11.9 g/dl) and plasma
B12 (787 ng/liter; normal range, 170–900) were normal. The
folate content was elevated in the serum (20 g/liter; normal
range, 1.6–13.2) and in red cells (1114 g/liter; normal range,
125–600). Plasma non-protein-bound homocystine was ele-
vated (9 M; normal, not detectable), and methionine was low
(14 M; normal range, 15–40). MMA was not elevated in urine.
Treatment consisted of betaine (9–15 g/day), folinic acid, which
was later changed to folic acid (15 mg/day), and OH-Cbl (1 mg
intramuscularly daily, later 1 mg weekly). After 1 week on
therapy, plasma non-protein-bound homocystine was not de-
tectable and the methionine level was normal (37 M). The
patient appeared more alert and had increased muscle tone in
all limbs with brisk tendon reflexes. Six months later he was
able to walk and became very vocal.
At 16 years of age, compliance with medication was good,
weight and height were between the 10th and 25th, and head
circumference was at the 10th percentile. He had nearly nor-
mal gait, could speak a number of single words, but required
help with dressing and washing; he could finger-feed and drink
from a cup but is incontinent. He showed erratic behavior,
hyperactivity, and aggression, and his sleep pattern was poor.
Although the intelligence quotient could not be formally as-
sessed, the patient was clearly severely mentally retarded.
Patient 2 was the first child of healthy unrelated Italian
parents. Pregnancy and delivery were unremarkable. At the
age of 3 months he presented with severe hypotonia, nystag-
mus, dystonic movements, and seizures that were difficult to
control with anticonvulsants. Brain MRI analysis showed re-
duced myelination and a small cerebellar vermis. Megaloblas-
tic anemia (mean corpuscular volume, 105 fl; hemoglobin, 8.5
g/dl; and hematocrit, 25.4%) with normal plasma folate and
slightly reduced B12 (156 ng/liter; normal range, 200–1000)
results were found. Plasma total homocysteine was elevated
(128 M; normal range, 5–16), and methionine decreased (4 M;
normal range, 15–54). MMA was not elevated in urine.
Betaine (Cystadane®, Orphan Europe, 200 mg/kg/day), folic
acid (15 mg/day), and OH-Cbl (1 mg/day) treatment resulted in
clinical and biochemical improvement. Seizures disappeared
within 10 days, and hematological status normalized. Plasma
total homocysteine decreased to 23 M, and methionine became
normal (38 M). At the age of 3 years, betaine was stopped and
OH-Cbl injections were reduced to 1 mg twice a week resulting
in slightly higher values of plasma total homocysteine (42 M).
Reintroduction of betaine (100 mg/kg/day) lowered plasma to-
tal homocysteine to 25 M.
At the age of 4 years his gross and fine motor skills were
normal. An MRI showed normal development of the brain,
however, speech delay was present and the intelligence quo-
tient assessed by the Stanford-Binet scale was 84.
Patient 3 was the second child of unrelated parents of Indian
origin, born at 32 weeks of gestation with a grade II respiratory
distress syndrome requiring artificial ventilation. Further com-
plications were grade I cranial hemorrhage, necrotizing entero-
colitis, and neonatal convulsions. MMA (978 mmol/mol creati-
nine; normal, 4) and methylcitrate (197 mmol/mol creatinine;
normal, not detectable) were markedly elevated in urine. Hemo-
globin and differential blood count were normal. Therapy with
intramuscular OH-Cbl (1 mg/week, later 2  0.5 mg/week), car-
nitine, protein restriction, and phenobarbital resulted in normal-
ization of metabolite excretion and the electroencephalogram.
Non-protein-bound homocystine was not detected in the plasma,
and later normal plasma total homocysteine (8.9 M) was found
even when treatment compliance was poor. Withdrawal of B12
therapy resulted in an increase of metabolite excretion (MMA:
18,425 mmol/mol creatinine; methylcitrate: 67 mmol/mol creati-
nine), which was readily reversed upon reintroduction of protein
restriction and B12 therapy.
At the age of 12 year the patient attended a special school
because of mild learning problems. Treatment continued as
done previously but compliance was poor and clinic attendance
was sporadic. Accordingly, MMA excretion was usually above
1000 mmol/mol creatinine, and his electroencephalogram was
abnormal. The intelligence quotient was 69 (Hawik-III test).
EXPERIMENTAL PROCEDURES
Cell Lines—Fibroblasts were grown from skin biopsies obtained with
informed consent of the patients or their parents. Cells were cultured in
Earle’s minimal essential medium supplemented with 10% fetal calf
serum, 2 mM L-glutamine, and antibiotics as described earlier (18).
Reference cell lines belonging to different cbl mutant classes were
characterized with methods described below and included five cblA, six
cblB, five cblC, nine cblE, and six cblG cell lines. The complementation
group of each of these cell lines was established by complementation
analysis using defined cell lines obtained from the Montreal Cell Re-
pository (cblE and cblG mutants) or cell lines in which complementation
analysis was earlier performed in the laboratory of Prof. D. Rosenblatt
(cblA, cblB, and cblC mutants). Cell lines WG1220 (one of the original
siblings with cblD defect), designated here as the original cblD cell line,
WG1575 (cblE), and WG1308 (cblG) were obtained from the Repository
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for Mutant Human Cell Strains (The McGill University-Montreal Chil-
dren’s Hospital Research Institute, Montreal, Canada).
Assays in Intact Fibroblast Monolayers—Incorporation of [14C]propi-
onate was assayed by a slight modification of the method described by
Willard et al. (19), and formation of [14C]methionine from [14C]formate
was determined as described earlier (20). Both assays were performed
in intact fibroblasts grown in normal and OH-Cbl-supplemented media.
Uptake of CN-[57Co]Cbl and cbl coenzyme synthesis from CN-
[57Co]Cbl was determined in intact fibroblasts as described earlier (21).
CN-[57Co]Cbl was bound to transcobalamin in normal human serum by
incubation for 30 min at 37 °C. Fibroblasts were incubated with me-
dium containing this serum at a final concentration of 10% (v/v) for 4
days in the dark. Cells were harvested, disrupted by freezing and
thawing, and cbl derivatives were extracted in hot ethanol and sepa-
rated by high performance liquid chromatography.
Specific Enzyme Assays—Fibroblasts were harvested by trypsiniza-
tion and cell free lysates prepared for enzyme assay. MMA-CoA mutase
activity was assayed by measuring the conversion of [14C]MMA-CoA to
[14C]succinyl-CoA in the presence (total mutase) and absence (holo-
mutase) of 50 M AdoCbl as described earlier (22). Methionine synthase
activity was measured under high reducing conditions (dithiothreitol,
28 mM) by measuring the formation of [14C]methionine from [14C]meth-
yltetrahydrofolate and L-homocysteine in the presence (total methio-
nine synthase) and absence (holo-methionine synthase) of 50 M MeCbl
(modified from Ref. 23). These two assays were performed in fibroblasts
cultured in normal and OH-Cbl supplemented (1 mg/liter) medium.
Cbl adenosyl transferase activity was determined by measuring the
conversion of OH-[57Co]Cbl to Ado[57Co]Cbl in an H2 atmosphere as
described (24), except that the total OH-Cbl concentration in the assay
mixture was 3.42 nM and OH-Cbl and AdoCbl were separated by high
performance liquid chromatography as described for cbl coenzyme syn-
thesis (see above). 5,10-Methylenetetrahydrofolate reductase (MTHFR)
was assayed in its physiological forward direction in the presence of 75
M flavin adenine dinucleotide as described earlier (18).
Somatic Cell Complementation Analysis—Complementation analy-
sis was performed by a modification of an earlier described method (25).
Briefly, heterokaryons were produced in mixed fibroblast cultures by
treatment with 40% (v/v) polyethylene glycol 1500 (Sigma P-7181) for
120 s. Three days later incorporation of [14C]propionate or formation of
[14C]methionine from [14C]formate was measured as described above.
Within each experiment mixed unfused cells, self fusions, and fusion of
cells from different known complementation groups were included as
background, negative, and positive controls, respectively. In addition,
patients’ cells were fused with cell lines belonging to at least two
different complementation groups to control the quality of the cells in
each individual experiment. Further, the presence of fused cells, indi-
cated by a characteristic enlarged cell structure, was confirmed by
microscopic examination.
Molecular Genetic Studies—Genomic DNA and total RNA were ex-
tracted from cultured skin fibroblasts and cDNA was synthesized from
RNA with standard protocols and kits (Invitrogen or Qiagen). The MTR
(cblG) and MTRR (cblE) genes, and genes shown to be implicated in the
reductive activation of methionine synthase (genes coding for NR1 and
cytochrome b5) were analyzed in patients 1 and 2 with isolated homo-
cystinuria. The MMAA (cblA) gene was analyzed in patient 3 with
isolated MMA-uria. Entire coding regions of the genes were PCR-am-
plified from cDNA and sequenced. Each identified genetic variant was
verified at the genomic DNA level using PCR-restriction fragment
length polymorphism or a PCR amplification refractory mutation
system.
For analysis of the MTR gene cDNA containing the entire coding
region (3798 bp) was amplified in four overlapping fragments (cDNA
positions 65–1088/1027–2033/1921–2953/2887–3852). M13-specific se-
quence tags were attached to each primer in the 5-position facilitating
DNA sequencing using a subsequent PCR reaction. Automated se-
quence analysis was performed using an ABI Prism 3700 sequencer
(Applied Biosystems) essentially as recommended by the manufacturer.
The entire MTRR coding sequence with its flanking 5- and 3-untrans-
lated regions was amplified in five overlapping segments employing
cDNA and sequenced as described previously (25) except for a 5-coding
region (exons 1–5). This region contains alternative isoforms, and there-
fore exons 1–5 were analyzed by sequencing of PCR products derived
from genomic DNA. The coding sequence of the MMAA gene was inves-
tigated by direct sequencing of PCR products derived from cDNA except
for exons 6 and 7 (3-coding region), which were analyzed by sequencing
of PCR products derived from genomic DNA using published primers
(8). The coding region of human NR1 was investigated by direct se-
quencing of PCR products derived from two overlapping cDNA frag-
ments using published primers (5). The coding region of human soluble
cytochrome b5 gene was investigated by direct sequencing in both
directions of PCR products derived from cDNA using primers contain-
ing the 15 nucleotides specific to the soluble isoform (26).
RESULTS
Enzyme Activities, cbl Uptake, and cbl Coenzyme Synthesis—
Activities of enzymes related to MMA and homocysteine me-
tabolism are shown in Tables I and II, respectively, and total
cbl uptake and coenzyme synthesis results are given in Table
III, in fibroblasts of the three patients, in reference cell lines
belonging to different cbl complementation groups, and in con-
trol fibroblasts.
Incorporation of propionate in intact fibroblasts measures
integrity of the propionate to the succinate pathway, which is
an indirect measure of MMA-CoA mutase activity. Similarly,
formation of methionine from formate in intact fibroblasts in-
directly measures the activity of methionine synthase. These
assays were performed in all cell lines to identify normal or
defective function of the corresponding pathways.
Enzyme Activities in Reference Cell Lines—We define isolated
TABLE I
Activities of enzymes related to methylmalonic acid metabolism in cultured skin fibroblasts
Fibroblasts were grown in basal medium without () and with () 10 g of hydroxocobalamin (OH-Cbl)/ml medium for propionate incorporation
assay, and in basal medium without and with 1 g of OH-Cbl/ml medium for methylmalonyl-CoA mutase assay. Methylmalonyl-CoA mutase was
assayed without (holo-enzyme activity) and with (total enzyme activity) 50 M adenosylcobalamin (AdoCbl). n  number of different control cell
lines. The values for patients 1, 2, and 3 are the means of duplicate determinations from three individual experiments, the values for the original
cblD cell line are the means of duplicate determinations from a representative experiment, and the values for the different cbl mutant cell lines
and control cell lines are the mean and range of results obtained in each cell line in a representative experiment with duplicate determinations.
Results of three OH-Cbl non-responsive and three OH-Cbl-responsive cblB cell lines are shown separately.
Propionate incorporation
Methylmalonyl-CoA mutase
Adenosyltransferase
Holo-enzyme (–AdoCbl) Total enzyme (AdoCbl)
nmol/16 h/mg protein pmol/min/mg protein fmol/h/mg protein
OH-Cbl in medium 3       
Patient 1 8.4, 9.8, 11 8.4, 9.5, 11 73, 93, 139 102, 135, 281 493, 753, 775 465, 875, 1185 3.1, 2.5, 1.9
Patient 2 6.2, 8.9, 9.4 6.4, 8.1, 11 90, 110, 117 104, 179, 192 938, 998, 765 919, 935, 778 0.71, 0.76, 1.2
Patient 3 1.3, 1.4, 1.9 16, 16, 14 12, 13, 78 46, 26, 23 1338, 2108, 554 916, 1446, 393 2.0, 2.5, 3.4
5 cblA cell lines 1.3 (0.73–2.0) 4.9 (2.8–7.4) 31 (18–45) 33 (13–69) 989 (544–1762) 247 (129–413) 1.9 (1.5–2.4)
3 cblB cell lines 1.4 (0.62–1.9) 3.6 (1.4–4.8) 26 (11–45) 34 (27–42) 1334 (884–1615) 845 (710–915) 0 (0–0.03)
3 cblB cell lines 1.0 (0.71–1.5) 1.2 (0.75–1.8) 38 (4.4–94) 36 (12–83) 1188 (554–1826) 786 (557–1086) 0 (0–0.001)
5 cblC cell lines 1.1 (0.24–1.8) 9.4 (2.5–19.6) 43 (15–95) 52 (30–127) 1178 (676–1627) 536 (150–813) 2.3 (1.8–3.2)
Original cblD 1.4 4.7 26 40 1376 828 2.8
9 cblE cell lines 10 (3.7–22) 10 (3.9–21)
6 cblG cell lines 11 (5.3–17) 11 (5.8–18)
Control cell lines 12 (6.4–18) 12 (5.2–21) 53 (24–106) 539 (265–1251) 1029 (575–2057) 1237 (585–2570) 1.2 (0.2–2.3)
n 13 13 24 24 24 24 12
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functional deficiency of MMA-CoA mutase, as seen in cblA and
cblB reference cell lines, as reduced incorporation of propionate,
reduced synthesis of AdoCbl combined with normal MeCbl syn-
thesis, and normal formation of methionine. Isolated functional
deficiency of methionine synthase, as seen in cblG and cblE
reference cell lines, was defined as reduced formation of methio-
nine, reduced synthesis of MeCbl with normal or elevated syn-
thesis of AdoCbl, and normal incorporation of propionate. All cell
lines belonging to the cblC complementation group as well as the
original cblD cell line showed combined functional deficiency of
MMA-CoA mutase and methionine synthase.
In vitro OH-Cbl responsiveness of the different cell lines,
evaluated by measuring incorporation of propionate or forma-
tion of methionine in cells grown in medium with added OH-
Cbl (10 mg/liter and 1.0 mg/liter, respectively), is shown in
Tables I and II. Responsiveness was defined as a reproducible,
approximate doubling of activity or more, reaching at least 25%
of the lowest control value in OH-Cbl supplemented medium
compared with activity in basal medium. Thus, all cblA and
cblC reference cell lines, three of the six cblB cell lines, the
original cblD cell line, and one of the six cblG cell lines were
OH-Cbl-responsive showing 2.3–10 times higher incorporation
of propionate or 2.7–106 times higher formation of methionine.
Levels of activities ranged from 27% to 381% of the lowest
control value. The other three cblB cell lines, five of the cblG
cell lines, and all nine cblE cell lines showed no such response
to OH-Cbl. In control cells, addition of OH-Cbl to the culture
medium had no or only a minor effect (maximum 40% increase)
on incorporation of propionate or formation of methionine. It
should be noted that our enzyme data in the different reference
cell lines, including the original cblD cell line, are similar to
those reported by others (15, 27).
Enzyme Activities in Fibroblasts of Patients 1 and 2—Results
of the enzyme assays clearly indicate isolated functional defi-
ciency of methionine synthase in patients 1 and 2. Thus, in both
patients’ cells, formation of methionine and MeCbl synthesis
were reduced whereas synthesis of AdoCbl was elevated and
incorporation of propionate was normal. Accordingly, the spe-
cific activity of methionine synthase was reduced under all
assay conditions, in cells grown in both basal and OH-Cbl
supplemented medium (Table II). The specific activity of total
MMA-CoA mutase was normal under all conditions. The rela-
tively high holo-mutase activity in unsupplemented medium
compared with controls may reflect the presence of elevated
levels of AdoCbl (Table III). It should be noted that there is a
tendency toward low holo-mutase activity in OH-Cbl-supple-
mented medium, the reason for which remains unclear. Fibro-
blasts of patients 1 and 2 showed a clear response to OH-Cbl
TABLE II
Activities of enzymes related to homocysteine metabolism in cultured skin fibroblasts
For methionine formation and methionine synthase assays fibroblasts were grown in basal medium without () supplementation and with ()
1 g of hydroxocobalamin (OH-Cbl)/ml. Methionine synthase was assayed without (holo-enzyme activity) and with (total enzyme activity) 50 M
methylcobalamin (MeCbl). 5,10-Methylenetetrahydrofolate reductase (MTHFR) activity was assayed in the presence of 75 M flavin adenine
dinucleotide. n  number of different control cell lines. The values for patients 1, 2, and 3 are the means of duplicate determinations from three
individual experiments, the values for the original cblD cell line are the means of duplicate determinations from a representative experiment, and
the values for the different cbl mutant cell lines and control cell lines are the mean and range of results obtained in each cell line in a representative
experiment with duplicate determinations. Results of five OH-Cbl non-responsive and one OH-Cbl-responsive cblG cell line are shown separately.
Methionine formation
Methionine synthase
MTHFR
Holo-enzyme (–MeCbl) Total enzyme (MeCbl)
nmol/16 h/mg protein pmol/min/mg protein nmol/h/mg
OH-Cbl in medium 3       
Patient 1 0.50, 0.58, 0.66 1.2, 1.9, 2.7 0.7, 3.4, 6.6 9.9, 28, 28 22, 56, 78 64, 66, 101 19.9, 33.2, 38.6
Patient 2 0.21, 0.43, 0.65 1.2, 1.2, 1.5 3.7, 4.7, 8.3 16, 19, 24 26, 38, 39 43, 44, 58 13.5, 14.5, 23.3
Patient 3 2.2, 2.2, 3.1 2.0, 2.6, 3.2 26, 29, 49 189, 194, 220 118, 130, 144 338, 356, 381 17.9, 21.6, 24.6
5 cblA cell lines 3.2 (2.3–4.2) 3.7 (3.0–4.3)
6 cblB cell lines 2.9 (2.4–3.4) 3.4 (2.9–4.2)
5 cblC cell lines 0.07 (0.03–0.19) 2.2 (1.3–3.6) 1.1 (0–3.4) 46 (10–141) 48 (7.8–93) 77 (40–195) 23.6 (10.5–39.1)
Original cblD 0.38 0.84 8.1 20 47 53 23.6
9 cblE cell lines 0.10 (0.04–0.23) 0.14 (0.03–0.37) 45 (21–77) 163 (92–217) 99 (51–136) 230 (163–317) 23.9 (17.8–42.9)
5 cblG cell lines 0.22 (0.03–0.29) 0.23 (0.03–0.34) 4.5 (2.1–7.1) 13 (2.0–29) 21 (1.4–53) 41 (1.4–128) 26.6 (19.8–49.6)
1 cblG cell line 0.63, 0.97, 1.0 2.2, 2.3, 2.4 3.2 17 14 54 23.9
Control cell lines 2.5 (1.4–4.3) 2.9 (1.7–5.0) 32 (13–56) 223 (88–496) 81 (33–159) 348 (139–625) 25.9 (14.5–54.6)
n 10 10 16 16 16 16 75
TABLE III
Total uptake of CN-57Cocobalamin and cobalamin coenzyme synthesis in fibroblasts
The values for patients 1, 2, and 3 are the means of duplicate determinations from three individual experiments, the values for the original cblD
cell line are the means of duplicate determinations from a representative experiment, and the values for the different cbl mutant cell lines and
control cell lines are the mean and range of results obtained in each cell line in a representative experiment with duplicate determinations.
Total uptake
Distribution of cobalamina
CN-Cbl OH-Cbl AdoCbl MeCbl Others
pg/mg protein % of total
Patient 1 34, 43, 56 12, 20, 24 7.5, 11, 8.1 77, 58, 65 2.9, 5.1, 3.3 0, 6.4, 0
Patient 2 62, 56, 57 23, 35, 24 16, 10, 5.8 55, 49, 65 5.6, 6.6, 5.0 0.6, 0, 0
Patient 3 76, 98, 76 17, 19, 20 7.8, 14, 9.2 8.2, 8.6, 5.3 67, 58, 66 0, 0, 0
5 cblA cell lines 58 (44–87) 20 (13–26) 17 (13–28) 7.7 (3.2–11) 55 (49–64) 0.2 (0–0.9)
6 cblB cell lines 64 (37–97) 22 (11–35) 18 (9.7–35) 7.0 (4.1–13) 53 (40–67) 0.1 (0–0.6)
5 cblC cell lines 9.1 (3.5–17) 73 (68–79) 16 (13–24) 6.4 (3.9–7.8) 3.5 (0–7.0) 1.0 (0–5.0)
Original cblD 17 46 30 10 14 0
9 cblE cell lines 54 (35–80) 26 (16–39) 34 (18–51) 25 (14–34) 12 (4.8–20) 3.7 (0–13)
6 cblG cell lines 64 (53–85) 13 (6.0–18) 22 (12–35) 58 (41–74) 5.6 (3.2–8.8) 1.8 (0–5.4)
Controls (n  23) 62 (39–119) 12 (6.0–17) 14 (4.7–28) 19 (14–26) 54 (39–69) 1.0 (0–5.6)
a CN-Cbl, cyanocobalamin; OH-Cbl, hydroxocobalamin; AdoCbl, adenosylcobalamin; MeCbl, methylcobalamin; n, number of different control cell
lines.
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with on average 3.1 and 3.4 times higher formation of methio-
nine, respectively, after growth with added OH-Cbl.
These findings were similar to those in the cblG cell lines,
especially a single one responsive to OH-Cbl, but different from
those in the cblE cell lines, which showed normal methionine
synthase activity in the presence of added reducing agent, and
were also not responsive to OH-Cbl. Levels of methionine syn-
thesis in basal medium in both patients were higher than in
cblC cell lines as also observed in the original cblD cell line.
Total cbl uptake was clearly normal in contrast to the reduced
values seen in cblC and the original cblD cells (Table III). The
activity of MTHFR was normal in both cell lines (Table II).
These findings provide clear evidence for an isolated defect of
MeCbl synthesis without impaired synthesis of AdoCbl in both
patients 1 and 2.
Enzyme Activities in Fibroblasts of Patient 3—Isolated func-
tional deficiency of MMA-CoA mutase was indicated by re-
duced incorporation of propionate and AdoCbl synthesis but
normal MeCbl synthesis and formation of methionine. Direct
assay of MMA-CoA mutase revealed markedly reduced holo-
mutase activity together with normal total mutase activities
(Table I) in cells grown both in basal and in OH-Cbl-supple-
mented medium. Methionine synthase activity was normal un-
der all assay and growth conditions (Table II).
Fibroblasts of patient 3 showed a dramatic response to OH-
Cbl with on average 10 times higher incorporation of propio-
nate after growth with OH-Cbl, values exceeding the mean
control value (Table I). This, together with clearly normal total
mutase activity, makes a mild form of MMA-CoA mutase
apoenzyme highly unlikely, because the highest total mutase
activity observed in 80 mut cell lines, including 11 with the
mut defect, was less than 50% of the lowest control value
(results not shown).
Comparison of enzyme activities allowed no distinction be-
tween cells of patient 3 and cblA except for low total mutase
activity in OH-Cbl-supplemented medium in the cblA cells but
not in patient 3. Cells of patient 3 could be clearly distinguished
from the OH-Cbl-responsive cblB cell lines by the presence of
normal cbl adenosyltransferase activity (Table I). These find-
ings provide clear evidence for an isolated defect of AdoCbl
synthesis without impaired MeCbl synthesis in patient 3.
Molecular Genetic Studies—Sequencing of the entire coding
regions of the MTR, MTRR, NR1, and cytochrome b5 genes in
patients 1 and 2, and of the MMAA gene in patient 3 revealed
no obvious pathogenic mutant alleles. A number of polymorphic
changes were observed as follows.
The missense mutation c.940G	A (D314N) of the MTR gene
was observed in patient 1 in the homozygous and in patient 2
in the heterozygous state and is known to be a polymorphism.2
Also in patient 1, three homozygous synonymous changes
(c.3144A	G, c.3492A	C, and c.3576C	T) of the MTR gene,
and nine heterozygous SNPs of the MTRR gene were identified,
all of which are known polymorphisms (28).2 Of the nine SNPs
of the MTRR gene two are missense mutations (c.66A	G and
c.1049A	G), five are synonymous changes (c.537T	C,
c.1464A	G, c.1536C	T, c.1761T	C, and c.1875G	A), and two
were detected in the 3-untranslated region of the gene
(c.2146A	G and c.2248A	G). This combination of SNPs in one
haplotype is unlikely to be pathogenic, because the same com-
bination was also identified in control chromosomes (data not
shown). In patient 2 heterozygosity for the known polymor-
phism (c.2756A	G) of the MTR gene (28) and homozygosity for
one genetic variant (c.66A	G) of the MTRR gene were found.
No polymorphisms were detected in the coding regions of the
MMAA, the NR1, or the cytochrome b5 genes.
Somatic Complementation Studies—Fig. 1 shows the results
of somatic complementation analysis, based on formation of
methionine, with cells of patient 1 and 2 tested with five cblC,
nine cblE, and six cblG cell lines, and the original cblD cell line.
The mean level of formation of methionine was 3.5–3.9 times
higher in cells of patient 1 and 2.6–2.8 times higher in cells of
patient 2 when fused with cblC, cblG, or cblE reference cell
lines as compared with mixed, unfused cells. In contrast, there
was no clear increase after self-fusion, fusion of fibroblasts of
the two patients with each other, or, importantly, after fusion
of fibroblasts of both patients with the original cblD cell line.
Thus, cells of both patients complemented all other cbl mutant
cell lines except the original cblD cell line allowing assignment
of patients 1 and 2 to the cblD complementation group, and we
define them as cblD-variant 1.
Fig. 2 shows the results of somatic complementation anal-
ysis, based on incorporation of propionate, with cells of pa-
tient 3 tested together with five cblA, six cblB, and five cblC2 Dr. B. Janosikova, personal communication
FIG. 1. Somatic complementation of fibroblasts of patients 1
(A) and 2 (B) with five cblC, the original cblD, nine cblE, and six
cblG cell lines. Fibroblasts of the patients were mixed with fibroblasts
belonging to these known complementation groups, fused with polyeth-
ylene glycol 1500 (PEG) treatment (shaded columns), and 3 days later
formation of methionine was measured as described under “Experimen-
tal Procedures.” Parallel cultures of mixed unfused cells were used as
background controls (unshaded columns). Self-fusions were used as a
negative control. Activities are the mean and the range (vertical lines)
of results from either different experiments with single determinations
(n*  number of individual experiments) or of results obtained with
different cell lines (n
  number of different cell lines). Each result with
a different cell line is the mean of results obtained in two individual
experiments with a single determination.
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cell lines and the original cblD cell line. The mean level of
incorporation of propionate was 4.0–4.3 times higher after
fusion with cblA, cblB, and cblC reference cell lines as com-
pared with mixed, unfused cells. In contrast self-fusion and,
importantly, fusion with the original cblD cell line led to no
clear increase of propionate incorporation (maximum, 10%
increase). Thus, cells of patient 3 complemented all other cell
lines investigated except the original cblD cell line allowing
assignment of patient 3 to the cblD complementation group,
and we define it as cblD-variant 2.
DISCUSSION
Our study in three new unrelated cblD patients with isolated
deficiency of either MeCbl or AdoCbl synthesis provides evi-
dence for heterogeneity within the cblD mutant class, which
was so far associated with combined deficiency of synthesis of
both cofactors (1). Somatic complementation studies revealed
that cells from patients 1 and 2 with isolated deficiency of
MeCbl synthesis clearly complemented reference cell lines with
this biochemical phenotype, namely cblE and cblG. Similarly,
cells from patient 3 with isolated deficiency of AdoCbl synthesis
complemented reference cell lines with the same biochemical
phenotype, i.e. cblA and cblB. Expanding the complementation
analysis with these three patients to include cblC reference cell
lines and the original cblD cell line, both with combined defi-
ciency of MeCbl and AdoCbl synthesis, revealed clear comple-
mentation with cblC cell lines, but no complementation with
the original cblD cell line in repeated experiments. This con-
clusively indicates that each of these 3 patients belongs to the
cblD complementation group, and they are designated as cblD-
variant 1 (patients 1 and 2) and cblD-variant 2 (patient 3). A
summary of our present understanding of the cellular and
metabolic pathways involved in B12 coenzyme biosynthesis is
shown in Fig. 3.
The cblD defect has been described in just two siblings in
whom combined functional deficiency of MMA-CoA mutase and
methionine synthase was demonstrated in cultured skin fibro-
blasts (15). The older sibling presented with developmental
delay and neurological abnormalities at the age of 14 years at
which time his 1.5-year-old affected sibling was apparently
healthy (14). Both siblings showed discrete signs of megaloblas-
tic anemia when studied later, at the ages of 26 and 13 years,
respectively (29). In contrast to the combined defect in these
original siblings, detailed studies in fibroblasts of our patients
1 and 2 provide clear evidence of an isolated defect of methio-
nine synthase. Accordingly, they presented with neurological
abnormalities and megaloblastic anemia without metabolic de-
compensation. Further, isolated functional MMA-CoA mutase
deficiency was confirmed in fibroblasts from our patient 3 who
presented with massive MMA-uria with normal plasma total
homocysteine and clinical signs compatible with MMA-emia.
Our study indicates that cblD mutants are not as rare as
reported. Thus, we detected the two cblD-variant 1 cell lines
among 17 with isolated functional methionine synthase defi-
ciency, and one cblD variant 2 cell line by investigation of 22
patients suspected to have the cblA defect.
It has been pointed out that biochemical differences between
the cblC and the original cblD cell lines are only quantitative
and that the two mutant classes are only distinguished by
complementation analysis (16). Since this original publication
no further cblD patients have been reported, whereas more
than one hundred patients belonging to the cblC complemen-
tation group have been described (1). Rosenblatt and Fenton (1)
raised the possibility that the mutation in the cblD defect
belongs to the same allele as in cblC and that the observed
complementation is interallelic. Interallelic complementation
has been shown to occur between different mutants of multim-
eric proteins and can be recognized by the occurrence of comple-
mentation between a variable number but not all cell lines of
the same mutant class. For example, complementation analy-
sis of 28 cell lines with mutations of the homotetrameric en-
zyme argininosuccinate lyase revealed 20 cell lines that com-
plemented between 1 and 14 of the other cell lines (30).
Similarly, within 10 cell lines with deficiency of the ho-
modimeric MMA-CoA mutase (mut0), 8 complemented 1 to 6 of
the others (31). In contrast to these and other examples, our 2
cblD-variant 1 cell lines clearly complemented each of a mini-
mum of 5 cell lines of the cblC, cblG, and cblE classes. Also the
cblD-variant 2 cell line complemented each of a minimum of 5
cell lines of the cblA, cblB, and cblC classes. Therefore our
findings support the idea of cblD as a separate entity, although
interallelic complementation cannot be completely excluded.
Further evidence that patients 1 and 2, and patient 3, do not
belong to the known complementation groups cblE and cblG, or
cblA, respectively, was provided by molecular genetic analysis
of the coding region of the relevant genes. Thus sequencing of
the MTRR (cblE) and MTR (cblG) genes in patients 1 and 2
revealed no potentially disease-causing mutations. Also, no
mutations in the coding region of the MMAA gene (cblA) were
detected in patient 3.
In addition, Olteanu and Banerjee (5) recently reported that
human NR1 can activate methionine synthase in the presence
of soluble cytochrome b5 and suggested that this enzyme might
fulfill a physiological function. Based on our previous observa-
tion that patient 1 cells complemented both cblE and cblG cell
lines (32), they suggested that a mutation in the NR1/soluble
cytochrome b5 system could be the cause of the defect in patient
1. However, sequencing of the coding regions of the NR1 and
soluble cytochrome b5 genes in patient 1 and 2 did not reveal
any mutations. Therefore, it is highly unlikely that either NR1
or cytochrome b5 is the protein responsible for the cblD comple-
mentation group.
In summary, we showed that none of the newly diagnosed
cblD patients carry pathogenic mutations in the tested genes as
listed above, thus strongly limiting the possibility that these
genes play a role in the pathogenesis of the cblD complemen-
tation group. Of course the presence of pathogenic mutations in
regulatory non-coding regions such as a promoter, which in
rare cases can cause disease, cannot be excluded.
The only known complementation groups related to intracel-
lular cbl metabolism that were not investigated in this study
FIG. 2. Somatic complementation of fibroblasts of patient 3
with five cblA, six cblB, and five cblC cell lines as well as the
original cblD cell line. Complementation was detected by the assay of
the incorporation of propionate 3 days after fusion. For details see
legend to Fig. 1.
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are cblF and cblH. The cblF defect is a rare disorder of cbl
release from the lysosomes leading to combined deficiency of
methionine synthase and MMA-CoA mutase function as also
seen in cblC reference cell lines (1, 10). A key feature of the cblF
defect, also found in our hands (data not shown), is elevated
total uptake of cbl reflecting its accumulation in lysosomes, in
the presence of deficient synthesis of both MeCbl and AdoCbl.
These findings clearly differ from those in our cblD variant cell
lines, and therefore this complementation group was not in-
cluded in this study.
The cblH complementation group was recently described by
Watkins et al. (7) in a single cell line from a patient with
isolated MMA-uria in which enzyme studies revealed isolated
functional deficiency of MMA-CoA mutase, as also seen in
patient 3. This cell line was not available to us. Assignment of
their patient to a new mutant class was based on complemen-
tation with mut, cblB, cblC, cblF, and several cblA cell lines but
not cblD (7, 27), raising the possibility that the newly described
cblH cell line could in fact belong to the cblD class of mutants.
The gene responsible for the cblD complementation group as
well as the function of the corresponding protein remain un-
known. However, this study shows that mutations in such a
protein most likely cause combined as well as isolated deficien-
cies of both AdoCbl and MeCbl synthesis. It could be speculated
that the systems, leading to synthesis of MeCbl and AdoCbl,
have different affinities for the cbl moiety produced by the cblD
protein. Then residual activity of the cblD protein may produce
sufficient product for the higher affinity, but not for the lower
affinity system thereby leading to sufficient synthesis of one cbl
coenzyme but not the other. However, this would explain the
existence of the combined defect and only one of the isolated
defects. A more likely explanation is that the cblD protein
contains at least three different domains, one cbl binding site,
one required for the “presentation” of the reduced cbl to cyto-
solic methionine synthase and one needed for presentation to a
mitochondrial membrane component. Thus, mutations within
the cbl binding domain or those leading to complete disruption
of the protein could result in reduced synthesis of both MeCbl
and AdoCbl as seen in the original cblD cell line. Mutations
within the methionine synthase recognition domain would af-
fect only the synthesis of MeCbl, whereas the cbl would be
available for AdoCbl synthesis as seen in the cblD-variant 1 cell
lines, and, accordingly, mutations within the mitochondrial
recognition domain would result in isolated deficiency of
AdoCbl synthesis as seen in cblD-variant 2, as illustrated in
Fig. 3. Another possible mechanism is that mitochondrial and
cytosolic isoforms of the cblD protein exist that are formed by
alternative splicing of a single gene. Thus mutations affecting
a shared functionally important domain would cause the com-
bined deficiency, whereas mutations causing defects in the
cytosolic form or in the mitochondrial isoform or mitochondrial
leader sequence would cause the two isolated deficiencies.
Finally, the unlikely possibility that the original cblD pa-
tients, who are consanguineous, have a defect in two independ-
ent genes cannot be ruled out. In this event one gene would be
deficient in variant 1 and the other in variant 2. This possibility
could have been ruled out by complementation analysis of
variants 1 and 2 with each other, but none of the available
methods revealed a common functional deficiency precluding
such an experiment.
In conclusion, our study shows that the cblD complementa-
tion group contains not only patients with combined deficiency
of the synthesis of both MeCbl and AdoCbl but also patients
with isolated deficiency of either MeCbl or AdoCbl synthesis.
FIG. 3. Summary of intracellular processing of cobalamin. Cbl, cobalamin; TCII, transcobalamin; OHCbl, hydroxocobalamin; MeCbl,
methylcobalamin; AdoCbl, adenosylcobalamin; cblA–cblG and mut, sites of defect in the various complementation groups as defined in the text;
variant 1 and variant 2, proposed sites of the cblD variants described in this study. The valence state of the cobalt atom of cobalamin is shown in
parentheses, with “? ” when not fully understood. Known enzymes are shown as follows: , methionine synthase reductase; , methionine synthase;
, cobalamin adenosyltransferase; , methylmalonyl-CoA mutase.
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However, the protein responsible for the cblD group as well as
its primary function remains to be detected. Our findings help
to delineate the pathways of intracellular cbl metabolism and
will help in identification of the so far unidentified correspond-
ing genes and proteins.
Acknowledgment—We thank Mira Gu¨nther for her excellent assist-
ance in the enzyme assays.
REFERENCES
1. Rosenblatt, D. S., and Fenton, W. A. (2001) in The Metabolic and Molecular
Bases of Inherited Disease (Scriver, C. R., Beaudet, A. L., Sly, W. S., and
Valle, D., eds) 8th Ed., pp. 3897–3933, McGraw-Hill, Inc., New York
2. Gulati, S., Baker, P., Li, Y. N., Fowler, B., Kruger, W., Brody, L. C., and
Banerjee, R. (1996) Hum. Mol. Genet. 5, 1859–1865
3. Leclerc, D., Wilson, A., Dumas, R., Gafuik, C., Song, D., Watkins, D., Heng,
H. H.Q., Rommens, J. M., Scherer, S. W., Rosenblatt, D. S., Rozen, R., and
Gravel, R. A. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 3059–3064
4. Watkins, D., and Rosenblatt, D. S. (1988) J. Clin. Invest. 81, 1690–1694
5. Olteanu, H., and Banerjee, R. (2003) J. Biol. Chem. 278, 38310–38314
6. Fenton, W. A., Gravel, R. A., and Rosenblatt, D. S. (2001) in The Metabolic and
Molecular Bases of Inherited Disease (Scriver, C. R., Beaudet, A. L., Sly,
W. S., and Valle, D., eds) 8th Ed., pp. 2165–2193, McGraw-Hill, Inc., New
York
7. Watkins, D., Matiaszuk, N., and Rosenblatt, D. S. (2000) J. Med. Genet. 37,
510–513
8. Dobson, C. M., Wai, T., Leclerc, D., Wilson, A., Wu, X., Dore`, C., Hudson, T.,
Rosenblatt, D. S., and Gravel, R. A. (2002) Proc. Natl. Acad. Sci. U. S. A. 99,
15554–15559
9. Dobson, C. M., Wai, T., Leclerc, D., Kadir, H., Narang, M., Lerner-Ellis, J. P.,
Hudson, T. J., Rosenblatt, D. S., and Gravel, R. A. (2002) Hum. Mol. Genet.
26, 3361–3369
10. Watkins, D., and Rosenblatt, D. S. (1986) Am. J. Hum. Genet. 39, 404–408
11. Pezacka, E. H. (1993) Biochim. Biophys. Acta 1157, 167–177
12. Watanabe, F., Saido, H., Yamaji, R., Miyatake, K., Isegawa, Y., Ito, A.,
Yubisui, T., Rosenblatt, D. S., and Nakano, Y. (1996) J. Nutr. 126,
2947–2951
13. Willard, H. F., Mellman, I. S., and Rosenberg, L. E. (1978) Am. J. Hum. Genet.
30, 1–13
14. Goodman, S. I., Moe, P. G., Hammond, K. B., Mudd, S. H., and Uhlendorf,
B. W. (1970) Biochem. Med. 4, 500–515
15. Fenton, W. A., and Rosenberg, L. E. (1978) Annu. Rev. Genet. 12, 223–248
16. Mellman, I. S., Willard, H. F., Youngdahl-Turner, P., and Rosenberg, L. E.
(1979) J. Biol. Chem. 254, 11847–11853
17. Watkins, D., and Rosenblatt, D. S. (1989) Am. J. Med. Genet. 34, 427–434
18. Suormala, T., Gamse, G., and Fowler, B. (2002) Clin. Chem. 48, 835–843
19. Willard, H. F., Ambani, L. M., Hart, A. C., Mahoney, M. J., and Rosenberg,
L. E. (1976) Hum. Genet. 34, 277–283
20. Fowler, B., Whitehouse, C., Wenzel, F., and Wraith, J. E. (1997) Pediatr. Res.
41, 145–151
21. Fowler, B., and Jakobs, C. (1998) Eur. J. Pediatr. 157, 88–93
22. Baumgartner, R. (1983) in The Cobalamins: Methods in Hematology (Hall,
C. A., ed) Vol. 10, pp. 181–195, Churchill Livingstone, Edinburgh, New York
23. Mellman, I., Willard, H. F., and Rosenberg, L. E. (1978) J. Clin. Invest. 62,
952–960
24. Fenton, W. A., and Rosenberg, L. E. (1981) Biochem. Biophys. Res. Commun.
98, 283–289
25. Zavadakova, P., Fowler, B., Zeman, J., Suormala, T., Pristoupilova, K., and
Kozich, V. (2002) J. Inherit. Metab. Dis. 25, 461–476
26. Giordano, S. J., and Steggles, A. W. (1991) Biochem. Biophys. Res. Commun.
178, 38–44
27. Cooper, B. A., Rosenblatt, D. S., and Watkins, D. (1990) Am. J. Hematol. 34,
115–120
28. Watkins, D., Ru, M., Hwang, H. Y., Kim, C. D., Murray, A., Philip, N. S., Kim,
W., Legakis, H., Wai, T., Hilton, J. H., Ge, B., Dore, C., Hosack, A., Wilson,
A., Gravel, R. A., Shane, B., Hudson, T. J., and Rosenblatt, D. S. (2002)
Am. J. Hum. Genet. 71, 143–153
29. Carmel, R., and Goodman, S. I. (1982) Blood 59, 306–311
30. McInnes, R. R., Shih, V., and Chilton, S. (1984) Proc. Natl. Acad. Sci . U. S. A.
81, 4480–4484
31. Qureshi, A. A., Crane, A. M., Matiaszuk, N. V., Rezvani, I., Ledley, F. D., and
Rosenblatt, D. S. (1994) J. Clin. Invest. 93, 1812–1819
32. Fowler, B., Suormala, T., Gu¨nther, M., Till, J., and Wraith, J. E. (1997)
J. Inherit. Metab. Dis. 20, Suppl. 1, 21 (abstract)
Three Unrelated Patients with cblD Defect 42749
 at U
ZH
 H
auptbibliothek / Zentralbibliothek Zuerich on February 20, 2020
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
Sewell, Jürgen Herwig and Brian Fowler
Kozich, Hans Georg Koch, Martin Berghaüser, James E. Wraith, Alberto Burlina, Adrian 
Terttu Suormala, Matthias R. Baumgartner, David Coelho, Petra Zavadakova, Viktor
and Adenosylcobalamin Synthesis
The cblD Defect Causes Either Isolated or Combined Deficiency of Methylcobalamin
doi: 10.1074/jbc.M407733200 originally published online August 2, 2004
2004, 279:42742-42749.J. Biol. Chem. 
  
 10.1074/jbc.M407733200Access the most updated version of this article at doi: 
 Alerts: 
  
 When a correction for this article is posted•  
 When this article is cited•  
 to choose from all of JBC's e-mail alertsClick here
  
 http://www.jbc.org/content/279/41/42742.full.html#ref-list-1
This article cites 30 references, 9 of which can be accessed free at
 at U
ZH
 H
auptbibliothek / Zentralbibliothek Zuerich on February 20, 2020
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
